hum0366-v1Release info

Pathogenesis of severe acute respiratory syndrome coronavirus 2 infection (COVID-19)

Aims

To analyze the immune response to the mRNA vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and pathophysiology of the coronavirus disease 2019 (COVID-19) and to provide insights into the clinical development.

Methods

single cell RNA-seq: Peripheral blood mononuclear cells from COVID-19 patients (with ARDS, n=8; without ARDS, n=8) and healthy controls (n=5) were analyzed by single cell RNA sequence.
RNA-seq: Total RNA extracted from monocytes derived from peripheral blood mononuclear cells of healthy subjects (n=4) was analyzed by RNA sequence.
ATAC-seq: DNA extracted from monocytes derived from peripheral blood mononuclear cells of healthy subjects (n=5) was analyzed by ATAC sequence.

Participants/materials

single cell RNA-seq: patients with COVID-19 (with ARDS, n=8; without ADRS, n=8), healthy subjects (n=5)
RNA-seq: healthy subjects (n=4 per person, PBMC)
ATAC-seq: healthy subjects (n=4 or 5 per person, PBMC)

URL

N/A

Principal investigator

Yasuhiro Kato

Affiliation

Department of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University

No research projects.